120. Zhuang CL, Ye XZ, Zhang XD, et al. Enhanced recovery after surgery programs versus traditional

care for colorectal surgery: a meta-analysis of randomized controlled trials. Dis Colon Rectum

2013;56(5):667–678.

121. Spanjersberg WR, Reurings J, Keus F, et al. Fast track surgery versus conventional recovery

strategies for colorectal surgery. Cochrane Database Syst Rev 2011(2):Cd007635.

122. ERAS Compliance Group. The impact of enhanced recovery protocol compliance on elective

colorectal cancer resection: results from an international registry. Ann Surg 2015;261(6):1153–

1159.

123. Monson JR, Weiser MR, Buie WD, et al. Standards Practice Task Force of the American Society of

Colon and Rectal Surgeons. Practice parameters for the management of rectal cancer (revised). Dis

Colon Rectum 2013;56(5):535–550.

124. Shiozawa M, Akaike M, Yamada R, et al. Clinicopathological features of skip metastasis in

colorectal cancer. Hepatogastroenterology 2007; 54(73):81–84.

125. Toyota S, Ohta H, Anazawa S. Rationale for extent of lymph node dissection for right colon cancer.

Dis Colon Rectum 1995;38(7):705–711.

126. Saha S, Johnston G, Korant A, et al. Aberrant drainage of sentinel lymph nodes in colon cancer and

its impact on staging and extent of operation. Am J Surg 2013;205(3):302–305; discussion 5–6.

127. Wiggers T, Jeekel J, Arends JW, et al. No-touch isolation technique in colon cancer: a controlled

prospective trial. Br J Surg 1988;75(5):409–415.

128. Heald RJ. The ‘Holy Plane’ of rectal surgery. J Royal Soc Med 1988;81(9):503–508.

129. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet

1993;341(8843):457–460.

130. Hohenberger W, Weber K, Matzel K, et al. Standardized surgery for colonic cancer: complete

mesocolic excision and central ligation–technical notes and outcome. Colorectal Dis 2009;11(4):354–

364; discussion 64–65.

131. Bertelsen CA, Neuenschwander AU, Jansen JE, et al. Disease-free survival after complete mesocolic

excision compared with conventional colon cancer surgery: a retrospective, population-based study.

Lancet Oncol 2015;16(2):161–168.

132. Nivatvongs S. Surgical management of malignant colorectal polyps. Surg Clin North Am

2002;82(5):959–966.

133. Haggitt RC, Glotzbach RE, Soffer EE, et al. Prognostic factors in colorectal carcinomas arising in

adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology

1985;89(2):328–336.

134. Butte JM, Tang P, Gonen M, et al. Rate of residual disease after complete endoscopic resection of

malignant colonic polyp. Dis Colon Rectum 2012;55(2):122–127.

135. Okabe S, Shia J, Nash G, et al. Lymph node metastasis in T1 adenocarcinoma of the colon and

rectum. J Gastrointest Surg 2004;8(8):1032–1039; discussion 9–40.

136. Kessler H, Hohenberger W. Extended lymphadenectomy in colon cancer is crucial. World J Surg

2013;37(8):1789–1798.

137. Nosho K, Kure S, Irahara N, et al. A prospective cohort study shows unique epigenetic, genetic, and

prognostic features of synchronous colorectal cancers. Gastroenterology 2009;137(5):1609–1620.e1–

3.

138. Yang C, Wexner SD, Safar B, et al. Conversion in laparoscopic surgery: does intraoperative

complication influence outcome? Surg Endosc 2009;23(11):2454–2458.

139. Fung AK, Aly EH. Systematic review of single-incision laparoscopic colonic surgery. Br J Surg

2012;99(10):1353–1364.

140. Kim CW, Kim CH, Baik SH. Outcomes of robotic-assisted colorectal surgery compared with

laparoscopic and open surgery: a systematic review. J Gastrointest Surg 2014;18(4):816–830.

141. Laurie JA, Moertel C, Fleming TR, et al. Surgical adjuvant therapy of large bowel carcinoma: an

evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol

1989;7:1447–1456.

142. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as

adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 1995;13(12):2936–2943.

143. Porschen R, Bermann A, Loffler T, et al. Fluorouracil plus leucovorin as effective adjuvant

1818

chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin

Oncol 2001;19(6):1787–1794.

144. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in

patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant

Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol

1999;17(5):1349–1355.

145. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for

resected colon cancer in elderly patients. N Eng J Med 2001;345(15):1091–1097.

146. Andre T, Boni C, Mounedi-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant

treatment for colon cancer. N Eng J Med 2004;350:2343–2351.

147. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and

leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol

2009;27(19):3109–3116.

148. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly

infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of Stage III

colon cancer: PETACC-3. J Clin Oncol 2009;27:3117–3125.

149. Allegra CJ, Yothers G, O’Connell MJ, et al. Bevacizumab in stage II-III colon cancer: 5-year update

of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 2013;31(3):359–

364.

150. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy

as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet

Oncol 2012; 13(12):1225–1233.

151. Alberts SR SD, Nair S, Mahoney MR, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or

without cetuximab on survival among patients with resected stage III colon cancer: a randomized

trial. JAMA 2012;307(13):1383–1393.

152. Schippinger W, Samonigg H, Schaberl-Moser R, et al. A prospective randomised phase III trial of

adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br

J Cancer 2007; 97(8):1021–1027.

153. Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with

colorectal cancer: a randomised study. Lancet 2007;370(9604):2020–2029.

154. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic

review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer

disease site group. J Clin Oncol 2004;22(16):3395–3407.

155. Marshall JL. Risk assessment in Stage II colorectal cancer. Oncology (Williston Park, NY) 2010;24(1

Suppl 1):9–13.

156. Ribic CM SD, Moore MJ, Thibodeau SN, et al. Tumor microsatellite-instability status as a predictor

of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Eng J Med

2003;349(3):247–257.

157. Nicholls RJ, Mason AY, Morson BC, et al. The clinical staging of rectal cancer. Br J Surg

1982;69(7):404–409.

158. Garcia-Aguilar J, Pollack J, Lee SH, et al. Accuracy of endorectal ultrasonography in preoperative

staging of rectal tumors. Dis Colon Rectum 2002;45(1):10–15.

159. Beets-Tan RG, Lambregts DM, Maas M, et al. Magnetic resonance imaging for the clinical

management of rectal cancer patients: recommendations from the 2012 European Society of

Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol

2013;23(9):2522–2531.

160. Heijnen LA, Lambregts DM, Martens MH, et al. Performance of gadofosveset-enhanced MRI for

staging rectal cancer nodes: can the initial promising results be reproduced? Eur Radiol

2014;24(2):371–379.

161. Hotker AM, Garcia-Aguilar J, Gollub MJ. Multiparametric MRI of rectal cancer in the assessment of

response to therapy: a systematic review. Dis Colon Rectum 2014;57(6):790–799.

162. Kwok H, Bissett IP, Hill GL. Preoperative staging of rectal cancer. Int J Colorectal Dis 2000;15(1):9–

20.

163. Bipat S, Glas AS, Slors FJ, et al. Rectal cancer: local staging and assessment of lymph node

1819